Market Research Logo

Radiopharmaceuticals Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Radiopharmaceuticals Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016-2024

Licensing, regulations, and use of radioisotopes in the U.S. is under agencies such as the U.S. Nuclear Regulatory Commission (NRC), the U.S. Environmental Protection Agency (EPA), the U.S. Food & Drug Administration (FDA), and respective state governments. The state governments are responsible for regulating radioactive substances that occur naturally or are produced by linear accelerators and/or cyclotrons, and EPA is responsible for among other things, setting air emission and drinking water standards for radionuclides. The U.S. Food and Drug Administration (FDA) regulates manufacturing and use of linear accelerators; granting marketing authorizations to radiopharmaceutical products for diagnostic as well as therapeutic use and other activities associated with radiopharmaceutical products.

Market Dynamics

Factors such as approval of products such as Lutathera, a potential blockbuster drug (Advanced Accelerator Applications, 2018) and Axumin (2016, Blue Earth Diagnostics) has propelled global radiopharmaceuticals in nuclear medicine market growth. Newer trends such as increasing therapeutic applications of radiopharmaceuticals and radiolabeling of monoclonal antibodies are expected to support growth of the market. Subsequently, as the need for early diagnosis of diseases such as cancer and accurate diagnosis of diseases such as Alzheimer's has become more necessary (certain products have come close to this such as Amyvid and Vizamyl) radiopharmaceuticals are expected to find an even strong foothold in medical care.

Key features of the study:

  • This report provides in-depth analysis of global radiopharmaceuticals in nuclear medicine market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global radiopharmaceuticals in nuclear medicine market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Inc., Pfizer, Inc., Actelion Pharmaceuticals, Alere, Inc., Trinity Biotech, Summit Therapeutics, Sanofi S.A., Novartis AG, and AstraZeneca Plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global radiopharmaceuticals in nuclear medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global radiopharmaceuticals in nuclear medicine market

Detailed Segmentation:
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type:
  • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
  • F-18 Florbetapir/Flutemetamol/ Florbetaben
  • F-18-Fluoro-Deoxy-Glucose (18F-FDG)
  • Fluorine-18 Fluciclovine
  • Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
  • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • Global Radiopharmaceuticals in Nuclear Medicine Market, By Region:
  • North America
  • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben

F-18-Fluoro-Deoxy-Glucose (18F-FDG)

Fluorine-18 Fluciclovine

Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
  • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
  • By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • By Country:
  • U.S.
  • Canada
  • Europe
  • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben

F-18-Fluoro-Deoxy-Glucose (18F-FDG)

Fluorine-18 Fluciclovine

Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
  • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
  • By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • By Country:
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben

F-18-Fluoro-Deoxy-Glucose (18F-FDG)

Fluorine-18 Fluciclovine

Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
  • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
  • By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • By Country:
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben

F-18-Fluoro-Deoxy-Glucose (18F-FDG)

Fluorine-18 Fluciclovine

Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
  • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
  • By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • By Country:
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East
  • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben

F-18-Fluoro-Deoxy-Glucose (18F-FDG)

Fluorine-18 Fluciclovine

Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
  • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
  • By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Diagnostic Nuclear Medicine
  • SPECT Radiopharmaceuticals
  • Tc-99m
  • In-111
  • Tl-201
  • Ga-67
  • I-123/I-125/I-131
  • Other SPECT Isotopes
  • PET Radiopharmaceuticals
  • F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben

F-18-Fluoro-Deoxy-Glucose (18F-FDG)

Fluorine-18 Fluciclovine

Other F-18 Isotopes
  • Ru-82
  • Other PET Isotopes
  • Therapeutic Nuclear Medicine
  • Ra-223
  • I-131
  • Re-186/Sm-153/Sr-90
  • Lu-177
  • Ir-192
  • Pd-103
  • Cs-131
  • Others
  • By Application:
  • Oncology
  • Cardiology
  • Neurology
  • Endocrinology
  • Others
  • By End User:
  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers
  • By Country/Region:
  • Central Africa
  • South Africa
  • North Africa
  • Company Profiles
  • Progenics Pharmaceuticals, Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • NorthStar Medical Radioisotopes LLC
  • Curium Pharma
  • Life Molecular Imaging
  • Lantheus Holdings, Inc.
  • Cardinal Health, Inc.
  • General Electric Company
  • Bracco S.p.A.
  • Bayer AG
  • Advanced Accelerator Applications, S.A.
  • Eli Lilly and Company
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and assumption
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Product Type
Market Snippet, By Application
Market Snippet, By End User
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Regulatory Scenario
Reimbursement Scenario
PEST Analysis
Porter’s Analysis
Collaborations & Partnerships
Mergers & Acquisitions
Key Developments
Epidemiology
4. Global Radiopharmaceuticals in Nuclear Medicine Market, By Product Type, 2016–2026 (US$ Mn)
Introduction
Market Share Analysis, 2017 and 2026 (%)
Y-o-Y Growth Analysis, 2018–2026
Segment Trends
Diagnostic Nuclear Medicine
SPECT Radiopharmaceuticals
Tc-99m
In-111
Tl-201
Ga-67
I-123/I-125/I-131
Other SPECT Isotopes
PET Radiopharmaceuticals
F-18
F-18 Florbetapir/Flutemetamol/ Florbetaben
F-18-Fluoro-Deoxy-Glucose (18F-FDG)
Fluorine-18 Fluciclovine
Other F-18 Isotopes
Ru-82
Other PET Isotopes
Therapeutic Nuclear Medicine
Ra-223
I-131
Re-186/Sm-153/Sr-90
Lu-177
Ir-192
Pd-103
Cs-131
Others
5. Global Radiopharmaceuticals in Nuclear Medicine Market, By Application, 2016–2026 (US$ Mn)
Introduction
Market Share Analysis, 2017 and 2026 (%)
Y-o-Y Growth Analysis, 2018–2026
Segment Trends
Oncology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Cardiology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Neurology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Endocrinology
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
6. Global Radiopharmaceuticals in Nuclear Medicine Market, By End User, 2016–2026 (US$ Mn)
Introduction
Market Share Analysis, 2017 and 2026 (%)
Y-o-Y Growth Analysis, 2018–2026
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Specialty Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
Diagnostic Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
7. Global Radiopharmaceuticals in Nuclear Medicine Market, By Regions, 2016–2026 (US$ Mn)
Introduction
Market Share Analysis, By Region, 2017 and 2026 (%)
Y-o-Y Growth Analysis, For Regions, 2018–2026
North America
Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
U.S.
Canada
Europe
Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of APAC
Latin America
Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
Brazil
Mexico
Rest of Latin America
Africa
Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
Central Africa
South Africa
North Africa
Middle East
Market Size and Forecast, By Product Type, 2016–2026 (US$ Mn)
Market Size and Forecast, By Application, 2016–2026 (US$ Mn)
Market Size and Forecast, By End User, 2016–2026 (US$ Mn)
Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
GCC
Israel
Rest of Middle East
8. Competitive Landscape
Heat Map Analysis
Company Profiles
Progenics Pharmaceuticals, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
NorthStar Medical Radioisotopes LLC
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Curium Pharma
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Life Molecular Imaging
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Lantheus Holdings, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Cardinal Health, Inc.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
General Electric Company
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Bracco S.p.A.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Bayer AG
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Advanced Accelerator Applications, S.A.
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Overview
Product Portfolio
Key Developments
Financial Performance
Strategies
9. Section
References
Research Methodology
About us and Sales Contact
*Browse 50 market data tables and 53 figures on "Radiopharmaceuticals in Nuclear Medicine Market - Global forecast to 2026”.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report